- Trial Phase
- Phase 1
- Time to Market
- Unknown — currently in Phase 1 dose-escalation; if successful, Phase 2/3 trials and potential approval would be several years away (likely 5+ years if ever).
- Why 6/10
- The next hard catalyst is the ACESOT-1051 Phase 1 clinical data update expected in Q4 2026 (roughly 1-3 months away). For a ~$10M market-cap company where APR-1051 is the lead and primary value driver, this update could drive a significant share-price move, but Phase 1 data is not a binary registrational catalyst, capping the impact score.
Watch for the Q4 2026 ACESOT-1051 clinical data update, which is the next major catalyst for this ~$10M micro-cap. The stock trades near its 52-week low with a strong analyst consensus (mean price target $3.73 vs ~$0.77 current), but massive warrant dilution (89.4M warrants vs 12.6M shares outstanding) and early-stage clinical risk cap the upside. Any positive efficacy/safety signal could drive a multi-bagger move; disappointing data could be devastating at this market cap.
Price Chart
Executive Summary
APR-1051 is Aprea Therapeutics' lead asset, an oral next-generation WEE1 kinase inhibitor in a first-in-human Phase 1 trial (ACESOT-1051, NCT06260514) for advanced solid tumors. Early data presented at ASCO 2026 showed a manageable safety profile with preliminary signals of antitumor activity, including two partial responses in biomarker-defined cancers. Enrollment is accelerating with sites expanding from 3 to 10, and the next clinical data update is expected in Q4 2026. Aprea is a micro-cap (~$10M market cap, stock ~$0.77) with strong analyst support (mean price target $3.73) and cash runway into Q1 2028, but faces significant risks from early-stage clinical development, massive warrant dilution (89.4M warrants vs 12.6M shares), and a competitive WEE1 inhibitor landscape.
How It Works
APR-1051 is an oral pill that blocks a protein called WEE1, which cancer cells use to repair DNA damage. By inhibiting WEE1, the drug prevents cancer cells from fixing their broken DNA, causing them to die. This approach (called DNA Damage Response inhibition) is designed to work in tumors with specific genetic mutations that already make them vulnerable to DNA damage.
Trial Status
The ACESOT-1051 trial (NCT06260514) is an ongoing first-in-human, open-label Phase 1 study evaluating oral APR-1051 in patients with advanced solid tumors. Enrollment is accelerating with sites expanding from 3 to 10. ASCO 2026 data (cutoff May 6, 2026) showed manageable safety and early monotherapy activity including two partial responses (one confirmed). The trial is dose-escalation with plans to expand into multiple cancer indications.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 — Next clinical data update from the ACESOT-1051 Phase 1 trial of APR-1051
- Potential expansion into additional cancer indications beyond the current solid-tumor cohort
- Possible partnership or licensing interest if Phase 1 data continues to improve
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Aprea Therapeutics, Inc. 8-K APRE ·Originating report